Genfit (OTCMKTS:GNFTF) Trading Down 4.1% – Here’s What Happened

Genfit S.A. (OTCMKTS:GNFTF)’s share price traded down 4.1% on Wednesday . The company traded as low as $10.43 and last traded at $10.43. 700 shares traded hands during mid-day trading, an increase of 19% from the average session volume of 590 shares. The stock had previously closed at $10.88.

Genfit Stock Down 4.1%

The firm’s 50-day moving average is $8.47 and its two-hundred day moving average is $5.71.

About Genfit

Genfit is a clinical‐stage biopharmaceutical company headquartered in Lille, France, specializing in the development of innovative therapies and diagnostics for liver and metabolic diseases. The company’s research and development efforts are primarily focused on non‐alcoholic steatohepatitis (NASH), a progressive liver disorder with significant unmet medical needs. Genfit’s lead therapeutic candidate, elafibranor, is designed to target key pathways involved in inflammation, fibrosis and lipid metabolism, positioning it as a potential treatment for patients with NASH and associated metabolic complications.

In addition to its therapeutic pipeline, Genfit has established a diagnostic arm centered on NIS4®, a proprietary blood‐based test that leverages transcriptomic biomarkers to enable earlier and more accurate detection of liver fibrosis in patients at risk for NASH.